Why the study?
Primary cardiomyopathies are an important group of heart disorders, prompting the evaluation of cardiomyopathy-related target genes and the phenotype-genotype relationship.
Does next-generation sequencing (NGS) identify pathogenic variants and contribute to clinical diagnosis in patients with suspected clinical cardiomyopathy?
Does next-generation sequencing (NGS) identify pathogenic variants and contribute to clinical diagnosis in patients with suspected clinical cardiomyopathy?
Next-generation sequencing in patients with suspected cardiomyopathy identified pathogenic or likely pathogenic variants in about a third of the identified variants, contributing to clinical diagnosis in 18.44% of cases.
NGS supports diagnostic evaluation in cardiomyopathy; leaves open larger prospective studies to clarify VUS impact and clinical utility.
Background: Primary heart muscle diseases called cardiomyopathy (CMP) constitute an important group of subsequent heart disorders. CMPs are basically divided into four subgroups associated with the heart muscle but clinically distinguishable: hypertrophic CMP (HCM), dilated CMP (DCM), restrictive CMP (RCM), and left ventricular non-compaction CMP. Material and Methods: The results of the patients who applied to the Genetic Diseases Evaluation Center with the preliminary diagnosis of clinical CMP were evaluated retrospectively in the current study. In the current study, 103 cases were included and evaluated for phenotype-genotype association with the CMP next-generation sequencing (NGS) panel. Results: Fifty-eight different variants were identified in 45 patients. Sixteen out of those 58 variants were novel. Of these variants, 19 (32.75%) were likely pathogenic (LP)/pathogenic (P), and 35 (60.34%) were variants of uncertain significance. Conclusion: The prevalence of pathogenic variants in target genes associated with CMP is important for our current country's population, and multiple gene groups associated with CMP can be screened through NGS. The contribution rate to the clinical diagnosis was 18.44% in terms of the individual population who applied to our medical genetics center and were compatible with the CMP indication.
No takes yet. Share an insight, caveat, or question.
Guler et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: